Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: Results of the randomized phase III study in recent-onset human type 1 diabetes

DEFEND Investigator Group

Research output: Contribution to journalComment/debate

Original languageEnglish (US)
Pages (from-to)S72
JournalDiabetes Technology and Therapeutics
Volume18
DOIs
StatePublished - Feb 2016

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Medical Laboratory Technology

Cite this